Potential use of radiolabelled neurotensin in PET imaging and therapy of patients with pancreatic cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73604427" target="_blank" >RIV/61989592:15110/20:73604427 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.researchgate.net/publication/339881267_Potential_use_of_radiolabelled_neurotensin_in_PET_imaging_and_therapy_of_patients_with_pancreatic_cancer" target="_blank" >https://www.researchgate.net/publication/339881267_Potential_use_of_radiolabelled_neurotensin_in_PET_imaging_and_therapy_of_patients_with_pancreatic_cancer</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/MNM.0000000000001172" target="_blank" >10.1097/MNM.0000000000001172</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Potential use of radiolabelled neurotensin in PET imaging and therapy of patients with pancreatic cancer

Popis výsledku v původním jazyce

Pancreatic cancer is the fourth leading cause of cancer-related death in both men and women. Neurotensin receptors are overexpressed in different malignancies, above all pancreatic cancer. On the other hand, neurotensin receptor expression in inflammation is quite low. This fact can probably solve the most important problem of F-FDG PET imaging - distinguishing malignant and inflammatory processes. The first therapeutic injection of radiolabelled neurotensin in human with pancreatic cancer has been successfully performed. Animal experiments are also very close to the first in human injection of radiolabelled neurotensin for diagnostic purposes. The purpose of this article is to provide an overview of radiolabelled neurotensin analogues that can be used in imaging and therapy in patients with pancreatic ductal adenocarcinoma.

Název v anglickém jazyce

Potential use of radiolabelled neurotensin in PET imaging and therapy of patients with pancreatic cancer

Popis výsledku anglicky

Pancreatic cancer is the fourth leading cause of cancer-related death in both men and women. Neurotensin receptors are overexpressed in different malignancies, above all pancreatic cancer. On the other hand, neurotensin receptor expression in inflammation is quite low. This fact can probably solve the most important problem of F-FDG PET imaging - distinguishing malignant and inflammatory processes. The first therapeutic injection of radiolabelled neurotensin in human with pancreatic cancer has been successfully performed. Animal experiments are also very close to the first in human injection of radiolabelled neurotensin for diagnostic purposes. The purpose of this article is to provide an overview of radiolabelled neurotensin analogues that can be used in imaging and therapy in patients with pancreatic ductal adenocarcinoma.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30224 - Radiology, nuclear medicine and medical imaging

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

NUCLEAR MEDICINE COMMUNICATIONS

ISSN

0143-3636

e-ISSN

—

Svazek periodika

41

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

"411 "- 415

Kód UT WoS článku

000531338900001

EID výsledku v databázi Scopus

2-s2.0-85083041368